It accelerates the AD process by exacerbating key pathological mechanisms, which include increased production and decreased clearance of amyloid-β (Aβ), acceleration of tau-related changes through mechanisms such as altered insulin signaling, and increased vascular damage, and changes in cerebral blood flow that can contribute to brain pathologies and cognitive deficits associated with AD [3]. This evidence concerns the gene MAPT and Alzheimer disease.